Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
Dancey J.E., Bedard P.L., Onetto N., Hudson T.J. The genetic basis for cancer treatment decisions. Cell 2012, 148:409-420.
Pleasance E.D., Cheetham R.K., Stephens P.J., McBride D.J., Humphray S.J., Greenman C.D., et al. A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 2010, 463:191-196.
Mardis E.R. The translation of cancer genomics: time for a revolution in clinical cancer care. Genome Med 2014, 6(3):22.
André F., Bachelot T., Commo F., Campone M., Arnedos M., Dieras V., et al. Comparative genomic hybridisation array and DNA sequencing to direct treatment of metastatic breast cancer: a multicentre, prospective trial (SAFIR01/UNICANCER). Lancet Oncol 2014, 15:267-274.
Eisenstein M. Foundation medicine. Nat Biotechnol 2012, 30:14.
Sleijfer S., Bogaerts J., Siu L.L. Designing transformative clinical trials in the cancer genome era. J Clin Oncol 2013, 31:1834-1841.
DeSantis C., Ma J., Bryan L., Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin 2014, 64(1):52-62.
Swain S.M., Baselga J., Kim S.B., Ro J., Semiglazov V., Campone M., et al. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 2015, 372:724-734.
Verma S., Miles D., Gianni L., Krop I.E., Welslau M., Baselga J., EMILIA Study Group, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012, 367:1783-1791.
Stephens P.J., Tarpey P.S., Davies H., Van Loo P., Greenman C., Wedge D.C., et al. The landscape of cancer genes and mutationam processes in breast cancer. Nature 2012, 486:400-404.
Cancer Genome Atlas Network Comprehensive molecular portraits of human breast tumours. Nature 2012, 490:61-70.
Gewinner C., Wang Z.C., Richardson A., Teruya-Feldstein J., Etemadmoghadam D., Bowtell D., et al. Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling. Cancer Cell 2009, 16:115-125.
Turner N., Lambros M.B., Horlings H.M., Pearson A., Sharpe R., Natrajan R., et al. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene 2010, 29:2013-2023.
Andre F., Job B., Dessen P., Tordai A., Michiels S., Liedtke C., et al. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res 2009, 15:441-451.
Stemke-Hale K., Gonzalez-Angulo A.M., Lluch A., Neve R.M., Kuo W.L., Davies M., et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 2008, 68:6084-6091.
Shah P.D., Moynahan M.E., Modi S., Caravella B.A., Datko F.M., Zamora S., et al. Phase I trial: PI3Kα inhibitor BYL719 plus aromatase inhibitor (AI) for patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC) 2014, SABSC, [Publication Number: PD5-3], 1424.
Turner N., Pearson A., Sharpe R., Lambros M., Geyer F., Lopez-Garcia M.A., et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 2010, 70:2085-2094.
Shiang C.Y., Qi Y., Wang B., Lazar V., Wang J., Fraser Symmans W., et al. Amplification of fibroblast growth factor receptor-1 in breast cancer and the effects of brivanib alaninate. Breast Cancer Res Treat 2010, 123:747-755.
André F., Cortés J. Rationale for targeting fibroblast growth factor receptor signaling in breast cancer. Breast Cancer Res Treat 2015, 150:1-8.
Arnedos M., Scott V., Job B., De La Cruz J., Commo F., Mathieu M.C., et al. Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: a clinical experience in 108 patients with metastatic breast cancer. Eur J Cancer 2012, 48:2293-2299.
Bose R., Kavuri S.M., Searleman A.C., Shen W., Shen D., Koboldt D.C., et al. Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov 2013, 3:224-237.
Finn R.S., Crown J.P., Lang I., Boer K., Bondarenko I.M., Kulyk S.O., et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol 2015, 16:25-35.
Hortobagyi G.N., Piccart-Gebhart M.J., Rugo H.S., Burris H.A., Campone M., Noguchi S., et al. Correlation of molecular alterations with efficacy of everolimus in hormone receptor-positive, HER2-negative breast cancer: results from BOLERO-2. J Clin Oncol 2013, 31. [suppl; abstr LBA509].
Baselga J., Campone M., Piccart M., Burris H.A., Rugo H.S., Sahmoud T., et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012 Feb 9, 366:520-529.
Loi S., Haibe-Kains B., Majjaj S., Lallemand F., Durbecq V., Larsimont D., et al. PIK3CA associated with gene signature of low mTORC1 signalingand better outcomes in estrogen receptor-positive breast cancer. Proc Natl Acad Sci USA 2010, 107:10208-10213.
Loi S., Michiels S., Baselga J., Bartlett J.M., Singhal S.K., Sabine V.S., et al. PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancer. PLoS One 2013, 8:e53292.
Bosco E.E., Wang Y., Xu H., Zilfou J.T., Knudsen K.E., Aronow B.J., et al. The retinoblastoma tumor suppressor modifies the therapeutic response of breast cancer. J Clin Inv 2007, 117:218-228.
Gerlinger M., Rowan A.J., Horswell S., Larkin J., Endesfelder D., Gronroos E., et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012 Mar 8, 366:883-892.
Burrel R.A., McGranahan N., Bartek J., Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 2013, 501:338-345.
Landau D.A., Klement K., Ziller M.J., Boyle P., Fan J., Gu H., et al. Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia. Cancer Cell 2014, 26:813-825.
André F., Mardis E., Salm M., Soria J.C., Siu L.L., Swanton C. Prioritizing targets for precision cancer medicine. Ann Oncol 2014, 25:2295-2303.
Haffner M.C., Mosbruger T., Esopi D.M., Fedor H., Heaphy C.M., Walker D.A., et al. Tracking the clonal origin of lethal prostate cancer. J Clin Invest 2013, 123:4918-4922.
Criscitiello C., Andre F., Thompson A.M., De Laurentiis M., Esposito A., Gelao L., et al. Biopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives. Breast Cancer Res 2014, 16:205.
Murtaza M., Dawson S.J., Tsui D.W.Y., Gale D., Forshew T., Piskorz A.M., et al. Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 2013, 497:108-112.
Arnedos M., Filleron T., Dieci M.V., Adam J., Robbins P.B., Loi S., et al. Genomic and immune characterization of metastatic breast cancer (mBC): an ancillary study of SAFIR01 & MOSCATO trials. Ann Oncol 2014, 25(Suppl 4):iv116-iv136.
Toy W., Shen Y., Won H., Green B., Sakr R.A., Will M., et al. ESR1 ligand binding domain mutations in hormone resistant breast cancer. Nat Genet 2013, 45:1439-1445.
Robinson D.R., Wu Y.M., Vats P., Su F., Lonigro R.J., Cao X., et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet 2013, 45:1446-1451.
Juric D., Castel P., Griffith M., Griffith O.L., Won H.H., Ellis H., et al. Convergent loss of PTEN leads to clinical resistance to PI(3)Kα inhibitor. Nature 2015, 518:240-244.
Miki Y., Swensen J., Shattuck-Eidens D., Futreal P.A., Harshman K., Tavtigian S., et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994, 266:66-71.
Wooster R., Bignell G., Lancaster J., Swift S., Seal S., Mangion J., et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995, 378:789-792.
Domchek S.M., Weber B.L. Clinical management of BRCA1 and BRCA2 mutation carriers. Oncogene 2006, 25:5825-5831.
Farmer H., McCabe N., Lord C.J., Tutt A.N., Johnson D.A., Richardson T.B., et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005, 434:917-921.
Tutt A., Robson M., Gaber J.E., Domchek S.M., Audeh M.W., Weitzel J.N., et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010, 376:235-244.
McNeish I., Coleman R., Oza A.M., Konecny G.E., O'Malley D., Kichenadasse G., et al. Preliminary results of ARIEL2, a phase 2 open-label study to identify ovarian cancer patients likely to respond to rucaparib. Ann Oncol 2014, 25(Suppl 4):iv305-iv326.
Alexandrov L.B., Nik-Zainal S., Wedge D.C., Aparicio S.A., Behjati S., Biankin A.V., et al. Signatures of mutational processes in human cancer. Nature 2013, 500:415-421.
Ku G.Y., Yuan J., Page D.B., Schroeder S.E., Panageas K.S., Carvajal R.D., et al. Singleinstitution experience with ipilimumab in advanced melanoma patients in the compassionate use s setting: lymphocyte count after 2 doses correlates with survival. Cancer 2010, 116:1767-1775.
Ji R.R., Chasalow S.D., Wang L., Hamid O., Schmidt H., Cogswell J., et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother 2012, 61:1019-1031.
Cha E., Klinger M., Hou Y., Cummings C., Ribas A., Faham M., et al. Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients. Sci Transl Med 2014, 6:238ra70.
Snyder A., Makarov V., Merghoub T., Yuan J., Zaretsky J.M., Desrichard A., et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Eng J Med 2014, 371:2189-2199.
Apetoh L., Ghirindelli F., Tesniere A., Obeid M., Ortiz C., Criollo A., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007, 13:1050-1059.
